利用腺相关病毒AAV1探究顺铂诱导的血管纹损伤中Gasdermin D的作用机制

doi:10.6040/j.issn.1673-3770.0.2025.041

摘要/Abstract

摘要： 目的探究含有细胞焦亡关键执行蛋白Gasdermin D(GSDMD)的基因片段及绿色荧光蛋白(Green fluorescent protein, GFP)标记的AAV1-GSDMD-GFP病毒对进行顺铂处理后的Gsdmd敲除小鼠(Gsdmd ^-/-)模型血管纹(Stria vascularis, SV)形态学影响。方法将Gsdmd ^-/-小鼠分为四组,分别为对照组(Gsdmd ^-/-)、空白对照组(Gsdmd ^-/-+AAV1-GFP)、顺铂处理组(Gsdmd -/-+Cisplatin)和回补GSDMD的顺铂处理组(Gsdmd -/-+AAV1-GSDMD-GFP +Cisplatin),通过荧光染色(Phalloidin、KCNQ1和GS-IB₄)来分析小鼠血管纹形态变化。结果 Gsdmd ^-/-+Cisplatin组小鼠可以抵抗顺铂耳毒性,成功回补GSDMD后,血管纹出现形态学上的异常(血管树突状断裂、细胞形态异常),表明GSDMD回补逆转了Gsdmd ^-/-小鼠的抵抗性。结论通过AAV1回补GSDMD可以逆转Gsdmd ^-/-小鼠血管纹对顺铂耳毒性的抵抗。

关键词: 腺相关病毒, 细胞焦亡, 顺铂耳毒性, 血管纹损伤

Abstract: Objective To investigate the morphological effects of AAV1-GSDMD-GFP virus, containing the gene fragment of the key pyroptosis execution protein Gasdermin D(GSDMD)labeled with green fluorescent protein(GFP), on the stria vascularis(SV)of Gsdmd knockout(Gsdmd ^-/-)mice after cisplatin treatment. Methods Gsdmd ^-/- mice were divided into four groups: Control(Gsdmd ^-/-), blank virus control(Gsdmd ^-/-+AAV1-GFP), cisplatin-treated(Gsdmd ^-/-+Cisplatin), and GSDMD-rescued(Gsdmd ^-/-+AAV1-GSDMD-GFP+Cisplatin). Morphological changes in the SV were analyzed via fluorescence staining(Phalloidin, Kcnq1, and GS-IB₄). Results The Gsdmd ^-/-+Cisplatin group exhibited resistance to cisplatin-induced ototoxicity. However, successful reintroduction of GSDMD via AAV1-GSDMD-GFP resulted in significant morphological abnormalities in the SV, including vascular dendritic fragmentation and cellular structural disruption, indicating that GSDMD restoration reversed the resistance phenotype. Conclusion Resistance to cisplatin ototoxicity in the stria vascularis of Gsdmd ^-/- mice can be reversed by AAV1 backfilling of GSDMD.

Key words: Adeno-associated virus, Pyroptosis, Cisplatin ototoxicity, Stria Vascularis Injury

中图分类号:

R764

张潇涵,朱立亚,肖雨,付小龙. 利用腺相关病毒AAV1探究顺铂诱导的血管纹损伤中Gasdermin D的作用机制[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 29-34.

ZHANG Xiaohan, ZHU Liya, XIAO Yu, FU Xiaolong. Investigating the mechanism of Gasdermin D in cisplatin-induced stria vascularis injury using adeno-associated virus AAV1[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 29-34.

参考文献

[1] Asaad W, Volos P, Maksimov D, et al. AAV genome modification for efficient AAV production[J]. Heliyon, 2023, 9(4): e15071. doi:10.1016/j.heliyon.2023.e15071
[2] Martinez-Navio JM, Paulk NK, Gao GP. Editorial: “AAV gene therapy: immunology and immunotherapeutics”[J]. Front Immunol, 2021, 12: 822389. doi:10.3389/fimmu.2021.822389
[3] Liu D, Zhu MY, Zhang YQ, et al. Crossing the blood-brain barrier with AAV vectors[J]. Metab Brain Dis, 2021, 36(1): 45-52. doi:10.1007/s11011-020-00630-2
[4] Dhungel BP, Bailey CG, Rasko JEJ. Journey to the center of the cell: tracing the path of AAV transduction[J]. Trends Mol Med, 2021, 27(2): 172-184. doi:10.1016/j.molmed.2020.09.010
[5] Dasari S, Njiki S, Mbemi A, et al. Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy[J]. Int J Mol Sci, 2022, 23(3): 1532. doi:10.3390/ijms23031532
[6] Ni MW, Zhou J, Zhu ZH, et al. Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe(2+)accumulation[J]. Phytomedicine, 2023, 112: 154701. doi:10.1016/j.phymed.2023.154701
[7] Li Q, Chen SW, Wang X, et al. Cisplatin-based combination therapy for enhanced cancer treatment[J]. Curr Drug Targets, 2024, 25(7): 473-491. doi:10.2174/0113894501294182240401060343
[8] Elmorsy EA, Saber S, Hamad RS, et al. Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies[J]. Eur J Pharm Sci, 2024, 203: 106939. doi:10.1016/j.ejps.2024.106939
[9] Qiao XY, Li W, Zheng ZW, et al. Inhibition of the HMGB1/RAGE axis protects against cisplatin-induced ototoxicity via suppression of inflammation and oxidative stress[J]. Int J Biol Sci, 2024, 20(2): 784-800. doi:10.7150/ijbs.82003
[10] Lu XC, Yin N, Chen C, et al. Mangiferin alleviates cisplatin-induced ototoxicity in sensorineural hearing loss[J]. Biomed Pharmacother, 2024, 178: 117174. doi:10.1016/j.biopha.2024.117174
[11] Li Y, Zeng S, Zhou FJ, et al. Overexpression of XIAP inhibits cisplatin-induced hair cell loss[J]. Biochim Biophys Acta Mol Cell Res, 2022, 1869(4): 119204. doi:10.1016/j.bbamcr.2021.119204
[12] Li ZZ, Yao QX, Tian YX, et al. Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy[J]. Biochem Pharmacol, 2022, 197: 114904. doi:10.1016/j.bcp.2021.114904
[13] Liu ZY, Zhang HB, Hong GD, et al. Inhibition of Gpx4-mediated ferroptosis alleviates cisplatin-induced hearing loss in C57BL/6 mice[J]. Mol Ther, 2024, 32(5): 1387-1406. doi:10.1016/j.ymthe.2024.02.029
[14] Sung CYW, Hayase N, Yuen PST, et al. Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity[J]. Sci Adv, 2024, 10(30): eadk9878. doi:10.1126/sciadv.adk9878
[15] Li M, Liu JW, Liu D, et al. Naringin attenuates cisplatin- and aminoglycoside-induced hair cell injury in the zebrafish lateral line via multiple pathways[J]. J Cell Mol Med, 2021, 25(2): 975-989. doi:10.1111/jcmm.16158
[16] Lyu AR, Kim SJ, Park MJ, et al. CORM-2 reduces cisplatin accumulation in the mouse inner ear and protects against cisplatin-induced ototoxicity[J]. J Adv Res, 2024, 64: 183-194. doi:10.1016/j.jare.2023.11.020
[17] Wang XL, Zhou YY, Wang DL, et al. Cisplatin-induced ototoxicity: From signaling network to therapeutic targets[J]. Biomed Pharmacother, 2023, 157: 114045. doi:10.1016/j.biopha.2022.114045
[18] Shen XJ, Wang HB, Weng CH, et al. Caspase 3/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity[J]. Cell Death Dis, 2021, 12(2): 186. doi:10.1038/s41419-021-03458-5
[19] Xu JJ, Zhang B, Chu ZL, et al. Wogonin alleviates cisplatin-induced cardiotoxicity in mice via inhibiting gasdermin D-mediated pyroptosis[J]. J Cardiovasc Pharmacol, 2021, 78(4): 597-603. doi:10.1097/FJC.0000000000001085
[20] Liu X, Xia SY, Zhang ZB, et al. Channelling inflammation: gasdermins in physiology and disease[J]. Nat Rev Drug Discov, 2021, 20(5): 384-405. doi:10.1038/s41573-021-00154-z
[21] Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death[J]. Cell Mol Immunol, 2021, 18(5): 1106-1121. doi:10.1038/s41423-020-00630-3
[22] Zhang ZB, Zhang Y, Lieberman J. Lighting a fire: can we harness pyroptosis to ignite antitumor immunity?[J]. Cancer Immunol Res, 2021, 9(1): 2-7. doi:10.1158/2326-6066.CIR-20-0525
[23] Ai YL, Wang WJ, Liu FJ, et al. Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P[J]. Cell Res, 2023, 33(12): 904-922. doi:10.1038/s41422-023-00848-6
[24] Loveless R, Bloomquist R, Teng Y. Pyroptosis at the forefront of anticancer immunity[J]. J Exp Clin Cancer Res, 2021, 40(1): 264. doi:10.1186/s13046-021-02065-8
[25] Zhang N, Zhang J, Yang YX, et al. A palmitoylation-depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis[J]. Nat Cell Biol, 2024, 26(5): 757-769. doi:10.1038/s41556-024-01397-9
[26] Xing YQ, Zhang FY, Ji PP, et al. Efficient delivery of GSDMD-N mRNA by engineered extracellular vesicles induces pyroptosis for enhanced immunotherapy[J]. Small, 2023, 19(20): e2204031. doi:10.1002/smLl.202204031
[27] Li LR, Chen L, Sun ZJ. Igniting hope: harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy[J]. Life Sci, 2024, 354: 122951. doi:10.1016/j.lfs.2024.122951
[28] Balasubramanian A, Hsu AY, Ghimire L, et al. The palmitoylation of gasdermin D directs its membrane translocation and pore formation during pyroptosis[J]. Sci Immunol, 2024, 9(94): eadn1452. doi:10.1126/sciimmunol.adn1452
[29] Crane R, Conley SM, Al-Ubaidi MR, et al. Gene therapy to the retina and the cochlea[J]. Front Neurosci, 2021, 15: 652215. doi:10.3389/fnins.2021.652215
[30] Taiber S, Cohen R, Yizhar-Barnea O, et al. Neonatal AAV gene therapy rescues hearing in a mouse model of SYNE4 deafness[J]. EMBO Mol Med, 2021, 13(2): e13259. doi:10.15252/emmm.202013259
[31] Marcovich I, Baer NK, Shubina-Oleinik O, et al. Optimized AAV vectors for TMC1 gene therapy in a humanized mouse model of DFNB7/11[J]. Biomolecules, 2022, 12(7): 914. doi:10.3390/biom12070914
[32] Qi JY, Zhang LY, Tan FZ, et al. Preclinical efficacy and safety evaluation of AAV-OTOF in DFNB9 mouse model and nonhuman primate[J]. Adv Sci, 2024, 11(3): 2306201. doi:10.1002/advs.202306201
[33] Qi JY, Tan FZ, Zhang LY, et al. AAV-mediated gene therapy restores hearing in patients with DFNB9 deafness[J]. Adv Sci, 2024, 11(11): 2306788. doi:10.1002/advs.202306788
[34] Zhang L, Song WA, Li H, et al. 4-octyl itaconate alleviates cisplatin-induced ferroptosis possibly via activating the NRF2/HO-1 signalling pathway[J]. J Cell Mol Med, 2024, 28(7): e18207. doi:10.1111/jcmm.18207
[35] Jiang YM, Li ZZ, Ma Q, et al. Aucubin protects mouse cochlear hair cells from cisplatin-induced ototoxicity via activation of the PI3K/AKT/STAT3 pathway[J]. Biochem Pharmacol, 2023, 209: 115440. doi:10.1016/j.bcp.2023.115440
[36] Bovee S, Klump GM, Köppl C, et al. The stria vascularis: renewed attention on a key player in age-related hearing loss[J]. Int J Mol Sci, 2024, 25(10): 5391. doi:10.3390/ijms25105391
[37] Lang HN, Noble KV, Barth JL, et al. The stria vascularis in mice and humans is an early site of age-related cochlear degeneration, macrophage dysfunction, and inflammation[J]. J Neurosci, 2023, 43(27): 5057-5075. doi:10.1523/JNEUROSCI.2234-22.2023
[38] Fang J, Li ZZ, Wang PJ, et al. Inhibition of the NLRP3 inflammasome attenuates spiral ganglion neuron degeneration in aminoglycoside-induced hearing loss[J]. Neural Regen Res, 2025, 20(10): 3025-3039. doi:10.4103/NRR.NRR-D-23-01879

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed